Trial | NCT02216513  Report issue

Title

Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage
Deferoxamine: An Emerging Therapy to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage

  • Phase

    Early Phase 1

  • Study Type

    Interventional

  • Status

    Terminated

  • Intervention/Treatment

    deferoxamine ...

  • Study Participants

    2
The investigators will test the central hypothesis that DFO treatment after SAH may improve cerebrovascular regulation, mitigate ischemic neural injury, and serve as an effective neuroprotectant against delayed ischemic injury after SAH.
Study Started
Sep 30
2014
Primary Completion
Jun 30
2015
Study Completion
Jul 31
2015
Last Update
Jul 21
2015
Estimate

Drug desferrioxamine (DFO)

DFO (20mg/kg/hr) in normal saline for 4 hours for 5 consecutive days

  • Other names: deferoxamine, desferal, DFO, deferoxamine mesylate

Drug placebo

normal saline IV for 4 hours for 5 consecutive days

  • Other names: normal saline NS

Desferrioxamine (DFO) Active Comparator

DFO (20mg/kg/hr) in normal saline IV for 4 hours for 5 consecutive days

placebo Placebo Comparator

normal saline IV for 4 hours for 5 consecutive days

Criteria 

Inclusion Criteria:

diagnosis of spontaneous SAH
impaired cerebral autoregulation on day 2-4 post SAH

Exclusion Criteria:

traumatic SAH
other central neurological disorders such as tumors, known prior stroke, hemorrhage or vascular malformations
pregnancy
severe renal disease or anuria
No Results Posted